This study compares the impact of the 3 different out-of-pocket maximums proposed in Congress and by the Medicare Payment Advisory Commission.
Sonal Parasrampuria, PhD, MPH
Advertisement
Articles by Sonal Parasrampuria, PhD, MPH
Out-of-pocket (OOP) spending for specialty drugs is substantially higher in Medicare Part D compared with employer-sponsored insurance because of the Part D benefit design.
Advertisement
Latest Updated Articles
- Comparing Patient OOP Spending for Specialty Drugs in Medicare Part D and Employer-Sponsored Insurance
Published: September 11th 2020 | Updated:
- Effects of an Out-of-Pocket Maximum in Medicare Part D
Published: February 7th 2022 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
Balancing Efficacy and Safety in BTKi Therapy
3
Measles Outbreaks Cause Financial, Public Health Burden in US
4
Empagliflozin Reduces HF Risk After AMI in Patients With or Without Diabetes, CKD
5
